CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2016; 37(01): 1-3
DOI: 10.4103/0971-5851.176979

Molecular functional imaging in personalized clinical oncology: The road less traveled

Abhishek Mahajan
Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
Subhash Desai
Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
Ameya Kawthalkar
Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
Meenakshi Thakur
Department of Radiodiagnosis, Tata Memorial Centre, Mumbai, Maharashtra, India
› Institutsangaben
Financial support and sponsorship Nil.


Artikel online veröffentlicht:
12. Juli 2021

© 2016. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

  • References

  • 1 Mahajan A, Goh V, Basu S, Vaish R, Weeks AJ, Thakur MH, et al. Bench to bedside molecular functional imaging in translational cancer medicine: To image or to imagine? Clin Radiol 2015;70:1060-82.
  • 2 Dhingra VK, Mahajan A, Basu S. Emerging clinical applications of PET based molecular imaging in oncology: The promising future potential for evolving personalized cancer care. Indian J Radiol Imaging 2015;25:332-41.
  • 3 Kalia M. Biomarkers for personalized oncology: Recent advances and future challenges. Metabolism 2015;64 3 Suppl 1:S16-21.
  • 4 Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
  • 5 O′Connor JP, Jackson A, Asselin MC, Buckley DL, Parker GJ, Jayson GC. Quantitative imaging biomarkers in the clinical development of targeted therapeutics: Current and future perspectives. Lancet Oncol 2008;9:766-76.
  • 6 Mahajan A, Engineer R, Chopra S, Mahanshetty U, Juvekar SL, Shrivastava SK, et al. Role of 3T multiparametric-MRI with BOLD hypoxia imaging for diagnosis and post therapy response evaluation of postoperative recurrent cervical cancers. European Journal of Radiology Open, 3, 2016. p. 22-30.
  • 7 Mahajan A, A V Moiyadi, R Jalali, E Sridhar. Radiogenomics of glioblastoma: a window into its imaging and molecular variability. Cancer Imaging 10/2015; 15 (Suppl 1): p. 14. DOI:10.1186/1470-7330-15-S1-P14.
  • 8 Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, et al. Theranostic applications of antibodies in oncology. Mol Oncol 2014;8:799-812.
  • 9 Katz R. Biomarkers and surrogate markers: An FDA perspective. NeuroRx 2004;1:189-95.
  • 10 NIH-FDA Conference: Biomarkers and surrogate endpoints: Advancing clinical research and applications. Abstracts. Dis Markers 1998;14:187-334.
  • 11 Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005;64:208-15.